📰 9 sources covering this story

Eli Lilly takes weight-loss pill battle global with first Foundayo approval in Europe

First covered 4 days ago · latest take 1 hrs ago. Compare how each outlet is covering it — and rate the sources you trust.

CNBC1 hrs ago

Lilly's Foundayo wins U.K. approval, taking its weight-loss pill battle with Novo Nordisk's Wegovy beyond the U.S. market.

Trust?Read on CNBC ↗

Quartz3 hrs ago

Eli Lilly's weight-loss pill is approved in the U.K.

The U.K. regulator authorized orforglipron for weight management and type 2 diabetes, making Britain the first country in Europe to clear the drug

Trust?Read on Quartz ↗

The Independent6 hrs ago

Foundayo: The new weight loss pill approved for the UK

Foundayo has been approved for treating weight loss as well as type 2 diabetes

Trust?Read on The Independent ↗

Reuters21 hrs ago

Eli Lilly's weight-loss pill secures first European nod in Britain

Eli Lilly's weight-loss pill secures first European nod in Britain Reuters

Trust?Read on Reuters ↗

Politico Europe1 days ago

UK approves its second weight-loss pill while EU access lags

A decision on whether Britain's National Health Service will cover the drug is expected in November.

Trust?Read on Politico Europe ↗

BBC Health1 days ago

New weight loss pill approved for use in UK

Foundayo is made by Eli Lilly, the drug firm behind the Mounjaro jab.

Trust?Read on BBC Health ↗

GB News1 days ago

UK becomes first in Europe to approve new once-daily weight loss pill

UK becomes first in Europe to approve new once-daily weight loss pill GB News

Trust?Read on GB News ↗

Sky News1 days ago

UK first in Europe to approve 'much cheaper' weight loss pill

The UK has become the first European nation to approve a pill which helps with weight loss and treats diabetes.

Trust?Read on Sky News ↗

New Scientist🏁 first to report4 days ago

Postbiotic supplement boosts body’s own GLP-1 and weight loss

A small trial suggests a supplement containing dead bacteria could offer a cheaper alternative to weight-loss drugs such as semaglutide, but further evidence is needed

Trust?Read on New Scientist ↗